NCT05143229
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05143229
Title Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET)
Acronym ASSET
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
The University of Kansas Clinical Research Center Fairway Kansas 66205 United States Details
The University of Kansas Cancer Center - Overland Park Overland Park Kansas 66210 United States Details
The University of Kansas Cancer Center - Indian Creek Overland Park Kansas 66211 United States Details
The University of Kansas Cancer Center Westwood Kansas 66205 United States Details
The University of Kansas Cancer Center - North Kansas City Hospital Kansas City Missouri 64116 United States Details
The University of Kansas Cancer Center - North Kansas City Missouri 64154 United States Details
The University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri 64064 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field